KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Acquisitions (2016)

Historic Acquisitions for Travere Therapeutics (TVTX) over the last 3 years, with Q4 2016 value amounting to $115000.0.

  • Travere Therapeutics' Acquisitions changed N/A to $115000.0 in Q4 2016 from the same period last year, while for Dec 2017 it was $115000.0, marking a year-over-year decrease of 8130.08%. This contributed to the annual value of $95.3 million for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q4 2016, Travere Therapeutics' Acquisitions is $115000.0.
  • In the past 5 years, Travere Therapeutics' Acquisitions ranged from a high of $33.4 million in Q1 2015 and a low of $115000.0 during Q4 2016
  • Its 3-year average for Acquisitions is $15.8 million, with a median of $14.8 million in 2014.
  • Within the past 5 years, the most significant YoY rise in Travere Therapeutics' Acquisitions was 1468.27% (2015), while the steepest drop was 1468.27% (2015).
  • Travere Therapeutics' Acquisitions (Quarter) stood at $29.2 million in 2014, then grew by 14.68% to $33.4 million in 2015, then crashed by 99.66% to $115000.0 in 2016.
  • Its Acquisitions was $115000.0 in Q4 2016, compared to $500000.0 in Q2 2016 and $33.4 million in Q1 2015.